710-31-6

Usage

Uses

Used in Pharmaceutical Development:
2-[(4-FLUOROPHENYL)AMINO]ACETOHYDRAZIDE is used as a precursor in the synthesis of new pharmaceutical drugs, leveraging its unique chemical structure to create novel therapeutic agents.
Used in Antimicrobial Applications:
2-[(4-FLUOROPHENYL)AMINO]ACETOHYDRAZIDE is used as an antimicrobial agent for its potential to combat various microorganisms, contributing to the development of new treatments for infectious diseases.
Used in Antifungal Applications:
2-[(4-FLUOROPHENYL)AMINO]ACETOHYDRAZIDE is used as an antifungal agent, harnessing its properties to inhibit the growth of fungi, which can be instrumental in treating fungal infections.
Used in Agricultural Chemistry:
2-[(4-FLUOROPHENYL)AMINO]ACETOHYDRAZIDE is used as a component in agricultural chemistry, potentially serving as a building block for the development of new agrochemicals to protect crops from pests and diseases.
Used in Organic Synthesis:
2-[(4-FLUOROPHENYL)AMINO]ACETOHYDRAZIDE is used as a reagent in organic synthesis, facilitating the creation of a variety of organic compounds for diverse applications across different industries.

InChI:InChI=1/C8H10FN3O/c9-6-1-3-7(4-2-6)11-5-8(13)12-10/h1-4,11H,5,10H2,(H,12,13)

Upstream product

• 2521-99-5 2-(4-fluorophenylamino)acetic acid ethyl ester 
• 371-40-4 4-fluoroaniline 

Downstream Products

• 436813-76-2 1-(N-p-fluorophenylamino)acetyl-4-phenyl thiosemicarbazide 
• 485330-04-9 5-((4-fluorophenylamino)methyl)-4-p-tolyl-4H-1,2,4-triazole-3-thiol 
• 298218-07-2 C₁₅H₁₄FN₃O₂ 
• 680594-43-8 [5-(N-p-fluorophenylamino)methyl-4-phenyl-1,2,4-triazol-3-yl]thioglycolylhydrazide 
• 333311-80-1 ethyl [5-(N-p-fluorophenylamino)methyl-4-phenyl-1,2,4-triazol-3-yl]thioglycolate 

Relevant academic research and scientific papers

Design and synthesis of new 2,5-disubstituted-1,3,4-oxadiazole analogues as anticancer agents

In continuance of our search for new anticancer agents, we report herein the design, synthesis, and anticancer evaluation of oxadiazole analogues. Two series (4a-h and 4i-q) of new oxadiazole analogues were designed based on heterocyclic (1,3,4-oxadiazole

Design, synthesis, structural characterization by IR, 1H, 13C, 15N, 2D-NMR, X-ray diffraction and evaluation of a new class of phenylaminoacetic acid benzylidene hydrazines as pfenr Inhibitors

Recent studies have revealed that plasmodial enoyl-ACP reductase (pfENR, FabI), one of the crucial enzymes in the plasmodial type II fatty acid synthesis II (FAS II) pathway, is a promising target for liver stage malaria infections. Hence, pfENR inhibitors have the potential to be used as causal malarial prophylactic agents. In this study, we report the design, synthesis, structural characterization and evaluation of a new class of pfENR inhibitors. The search for inhibitors began with a virtual screen of the iResearch database by molecular docking. Hits obtained from the virtual screen were ranked according to their Glide score. One hit was selected as a lead and modified to improve its binding to pfENR; from this, a series of phenylamino acetic acid benzylidene hydrazides were designed and synthesized. These molecules were thoroughly characterized by IR, 1H, 13C, 15N, 2D-NMR (COSY, NOESY, 1H-13C, 1H-15N HSQC and HMBC), and X-ray diffraction. NMR studies revealed the existence of conformational/configurational isomers around the amide and imine functionalities. The major species in DMSO solution is the E, E form, which is in dynamic equilibrium with the Z, E isomer. In the solid state, the molecule has a completely extended conformation and forms helical structures that are stabilized by strong hydrogen bond interactions, forming a helical structure stabilized by N-H...O interactions, a feature unique to this class of compounds. Furthermore, detailed investigation of the NMR spectra indicated the presence of a minor impurity in most compounds. The structure of this impurity was deduced as an imidazoline-4-one derivative based on 1H-13C and 1H-15H HMBC spectra and was confirmed from the NOESY spectra. The molecules were screened for in vitro activity against recombinant pfENR enzyme by a spectrophotometric assay. Four molecules, viz. 17, 7, 10, and 12 were found to be active at 7, 8, 10, and 12?μm concentration, respectively, showing promising pfENR inhibitory potential. A classification model was derived based on a binary QSAR approach termed recursive partitioning (RP) to highlight structural characteristics that could be tuned to improve activity.

Ion Channel Modulators

The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.

ION CHANNEL MODULATORS

The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein cab be used for the therapeutic modulation of ion channel fu